This company has been marked as potentially delisted and may not be actively trading. NASDAQ:EPZM Epizyme (EPZM) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Epizyme Stock (NASDAQ:EPZM) 30 days 90 days 365 days Advanced Chart Get Epizyme alerts:Sign Up Key Stats Today's Range$1.47▼$1.4750-Day Range$1.47▼$1.5252-Week Range$0.41▼$5.80Volume7,960 shsAverage Volume3.23 million shsMarket Capitalization$247.44 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. Read More Receive EPZM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Epizyme and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EPZM Stock News Headlinesbluebird bio Inc BLUENovember 1, 2023 | morningstar.comMCelgene, Jounce Therapeutics in Early Cancer Immunotherapy Development PactMarch 21, 2023 | thestreet.comGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—not the government—have been handed control of a new class of programmable money. It’s not called a CBDC, but it acts just like one. Your spending could be tracked, limited, or even frozen—whether you opt in or not. Once this system becomes the default, escape won’t be easy.September 2 at 2:00 AM | Priority Gold (Ad)Aptinyx's (APTX) Mid-Stage Fibromyalgia Study Fails to Meet Goal - NasdaqAugust 12, 2022 | nasdaq.comForm SC 14D9/A Epizyme, Inc. Filed by: Epizyme, Inc. - StreetInsider.comAugust 12, 2022 | streetinsider.comThe past five years for Epizyme (NASDAQ:EPZM) investors has not been profitableAugust 10, 2022 | finance.yahoo.comEpizyme: Q2 Earnings Insights - BenzingaAugust 9, 2022 | benzinga.comEpizyme Reports Second Quarter 2022 Financial Results and Provides Business Update - Business WireAugust 9, 2022 | businesswire.comSee More Headlines EPZM Stock Analysis - Frequently Asked Questions How were Epizyme's earnings last quarter? Epizyme, Inc. (NASDAQ:EPZM) issued its earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.48) by $0.16. The business's revenue for the quarter was up 45.8% on a year-over-year basis. What other stocks do shareholders of Epizyme own? Based on aggregate information from My MarketBeat watchlists, some other companies that Epizyme investors own include Novavax (NVAX), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), Pfizer (PFE), Applied Materials (AMAT) and Advanced Micro Devices (AMD). Company Calendar Last Earnings11/09/2021Today9/02/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:EPZM CIK1571498 Webwww.epizyme.com Phone(617) 229-5872Fax617-349-0707Employees250Year Founded2007Profitability EPS (Trailing Twelve Months)($1.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$251.12 million Net Margins-391.90% Pretax Margin-391.80% Return on Equity-2,459.33% Return on Assets-69.74% Debt Debt-to-Equity RatioN/A Current Ratio5.35 Quick Ratio5.19 Sales & Book Value Annual Sales$37.43 million Price / Sales6.61 Cash FlowN/A Price / Cash FlowN/A Book Value($0.54) per share Price / Book-2.72Miscellaneous Outstanding Shares168,329,000Free Float128,968,000Market Cap$247.44 million OptionableOptionable Beta-0.41 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:EPZM) was last updated on 9/2/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Epizyme, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Epizyme With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
